OBJECTIVES: Ustekinumab, a biologic used in moderate-to-severe plaque psoriasis (PsO), is dosed at 45mg or 90mg with health care provider (HCP) administration at weeks 0, 4, and every 12 weeks thereafter. The objective of this study was to evaluate the observed dosing patterns and HCP office visits for psoriasis patients receiving ustekinumab. METHODS: The IMS LifeLink™ database was utilized to analyze patients with an index pharmacy claim of ustekinumab therapy initiated September 25, 2009 to March 31, 2011. Inclusion criteria: patients aged ≥ 18 years at index, ≥ 1 PsO diagnosis code before or on index, and ≥ 360 days pre-index continuous enrollment. Ustekinumab dosing patterns included the proportion of 45mg and 90mg doses at each of the first four fills and the time between injections. Increases or decreases in dose between subsequent fills were assessed. Office visits were evaluated for the 180-day post-index time period (patients required ≥ 180 days post-index continuous enrollment). RESULTS: A total of 306 PsO patients receiving ustekinumab were evaluated.  The proportion of index 45mg/90mg use was 65%/35%. The proportion of 45mg use spanned 59%-61% across remaining fills. Median (mean± SD) interval times were 28 (30±20), 84 (87±32), and 85 (90±33) days for first to second, second to third, and third to fourth doses, respectively. Changes in dose were observed for ≤ 7% of patients at each fill. Patients (n=280) incurred a median (mean) number of 4 (5.5) all-cause and 3 (2.5) PsO-related HCP office visits during the first six-months after initiating therapy. CONCLUSIONS: These results suggest that most PsO patients are initiated with a 45 mg dose. Nearly 93% of all patients at each fill did not require dose changes over the first 4 prescriptions.  The observed interval patterns were consistent with the recommended ustekinumab administration schedule. Additionally, patients experienced PsO-related HCP interactions commensurate with the number of ustekinumab doses expected.